Atlas Venture and Lilly Ventures leads $8 mln round for Numerate

Biotech firm Numerate has closed $8 million in financing. Atlas Venture and Lilly Ventures led the round. In addition to the financing, Dr. Bruce Booth, a partner at Atlas Venture and Dr. Steve Hall, a venture partner at Lilly Ventures, have been added to Numerate’s board of directors.

Coherus BioSciences nabs $55 mln Series C

Coherus BioSciences has raised $55 million in Series C funding. The investors included KKR, Venrock, RA Capital Management, Rock Springs Capital, Fidelity Biosciences, Sofinnova Ventures, Lilly Ventures and Vivo Capital. Based in Redwood City, Calif., Coherus BioSciences is a biologics platform focused on biosimilars.

Atlas Venture leads seed round for Lysosomal Therapeutics

Lysosomal Therapeutics has secured $4.8 million in seed funding. Atlas Venture led the round with participation from Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners. Headquartered in Cambridge, Mass., Lysosomal Therapeutics develops molecules to be used to treat neurodegenerative diseases.

Nimbus Discovery Names Lynch Executive Chairman

Biotechnology company Nimbus Discovery has appointed Daniel Lynch has been appointed to the company’s board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., partner at Atlas Venture and co-founder of Nimbus, who will remain on the board. Nimbus is backed by life science investors including Atlas Venture, SR One, Lilly Ventures and Gates Ventures.

Sutro Biopharma Secures More Funds Led by Skyline Ventures

San Francisco-based Sutro Biopharma has closed a $16.5 million second tranche of its Series C financing. The financing was led by Skyline Ventures and included participation of Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners. Sutro has raised almost $60 million since its founding in 2003. PRESS RELEASE Sutro Biopharma today announced the […]

Cerulean Pharma Closes Series D

Cerulean Pharma, a developer of nanopharmaceuticals, has closed a $15 million Series D financing with participation from new investor, CVF, an affiliate of Henry Crown and Company of Chicago, Illinois, as well as full participation from all other existing investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, and Bessemer Venture Partners. Cerulean’s offices […]

Nimbus Discovery Inks $24M Series A

Biopharma company Nimbus Discovery has closed on a $24 million Series A round co-led by Atlas Venture, SR One, and Lilly Ventures. Existing investor, Bill Gates, also participated, the company said. Nimbus uses computational technology to discover medicines for difficult-to-drug diseases, and will use the infusion of capital to accelerate its existing development programs. The company closed on an undisclosed amount of seed financing in March.

FORMA Therapeutics Raises $25.5 Million

FORMA Therapeutics, a Cambridge, Mass.-based small molecule drug developer with an initial focus on cancer, has raised $25.5 million in Series B funding. Lilly Ventures led the round, and was joined by return backers Novartis Option Fund and Bio*One Capital. The company previously raised $25 million.

Lilly Ventures Spins Out from Eli Lilly

Lilly Ventures has spun out from drugmaker Eli Lilly & Co., in order to offer its employees more competitive compensation packages, according to VentureWire. As part of the deal, Lilly Ventures secured a new $200 million capital commitment from its former parent company. www.lillyventures.com

Alta Partners Invests in Avid Radiopharma

Avid Radiopharmaceuticals Inc., a developer of molecular imaging products, completed the first closing of a $34.5 million Series D financing led by Alta Partners. Existing investors AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group, LLC and BioAdvance. Press release: Avid Radiopharmaceuticals, Inc., a leader in the development of molecular imaging products, today […]

Hydra Biosciences Raises $22 Million in Series D Financing

Hydra Biosciences, a Cambridge, Mas.-based developer of novel ion channel drugs, raised $22 million in Series D financing led by MedImmune Ventures. Prior investors contributing follow-on commitments include Advanced Technology Ventures, Abingworth, Polaris, BioVenture Investors, Biogen-Idec Ventures, and Lilly Ventures in the Series D round. Hydra Biosciences has raised $47 million in previous rounds of […]

Intradigm Raises $18.5 Million

Intradigm Corp., a Palo Alto, Calif.-based developer of RNAi therapeutics, has raised $18.5 million in Series B funding. Lilly Ventures led the round, and was joined by Roche Venture Fund, MP Healthcare Venture Management and return backers Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund and Novartis Venture Fund.

PEHUB Community

Join the 12503 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget